Isofol Medical AB (publ) (FRA:5IU)
Germany
· Delayed Price · Currency is EUR 0.0531
-0.0021 (-3.80%)
At close: Dec 4, 2025
Isofol Medical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | - | - | 0.72 | 12.8 | 22.41 | 37.12 | Upgrade
|
| Revenue | - | - | 0.72 | 12.8 | 22.41 | 37.12 | Upgrade
|
| Revenue Growth (YoY) | - | - | -94.37% | -42.89% | -39.63% | - | Upgrade
|
| Cost of Revenue | 41.91 | 38.73 | 35.14 | 143.71 | 196.71 | 199.54 | Upgrade
|
| Gross Profit | -41.91 | -38.73 | -34.42 | -130.92 | -174.31 | -162.42 | Upgrade
|
| Selling, General & Admin | 14 | 8.48 | 7.42 | 34.75 | 27.72 | 22.74 | Upgrade
|
| Other Operating Expenses | -0.01 | -0.01 | -0.19 | 1.81 | 0.84 | -0.43 | Upgrade
|
| Operating Expenses | 13.99 | 8.48 | 7.27 | 36.63 | 30.16 | 24.08 | Upgrade
|
| Operating Income | -55.9 | -47.21 | -41.68 | -167.54 | -204.47 | -186.5 | Upgrade
|
| Interest Expense | -0 | - | -0.01 | - | -0.17 | -0.15 | Upgrade
|
| Interest & Investment Income | 1.9 | 3.72 | 4.57 | 0.15 | 0.01 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.5 | - | 0.05 | 3.79 | 0.84 | -0.33 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | - | - | 3.81 | 3.53 | -2.01 | Upgrade
|
| EBT Excluding Unusual Items | -54.49 | -43.49 | -37.07 | -159.79 | -200.25 | -188.99 | Upgrade
|
| Pretax Income | -54.49 | -43.49 | -37.07 | -159.79 | -200.25 | -188.99 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | 0 | Upgrade
|
| Net Income | -54.49 | -43.49 | -37.07 | -159.79 | -200.25 | -188.99 | Upgrade
|
| Net Income to Common | -54.49 | -43.49 | -37.07 | -159.79 | -200.25 | -188.99 | Upgrade
|
| Shares Outstanding (Basic) | 189 | 162 | 162 | 162 | 126 | 61 | Upgrade
|
| Shares Outstanding (Diluted) | 189 | 162 | 162 | 162 | 126 | 61 | Upgrade
|
| Shares Change (YoY) | 20.55% | - | - | 28.55% | 104.40% | 91.76% | Upgrade
|
| EPS (Basic) | -0.29 | -0.27 | -0.23 | -0.99 | -1.59 | -3.07 | Upgrade
|
| EPS (Diluted) | -0.29 | -0.27 | -0.23 | -0.99 | -1.59 | -3.07 | Upgrade
|
| Free Cash Flow | -48.84 | -41.99 | -52.54 | -192.68 | -188.43 | -160.27 | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -0.26 | -0.33 | -1.19 | -1.50 | -2.61 | Upgrade
|
| Operating Margin | - | - | -5781.41% | -1309.24% | -912.50% | -502.43% | Upgrade
|
| Profit Margin | - | - | -5141.61% | -1248.68% | -893.70% | -509.15% | Upgrade
|
| Free Cash Flow Margin | - | - | -7286.55% | -1505.66% | -840.94% | -431.77% | Upgrade
|
| EBITDA | -55.89 | -47.21 | -41.65 | -167.48 | -204.39 | -186.3 | Upgrade
|
| D&A For EBITDA | 0 | 0 | 0.04 | 0.07 | 0.08 | 0.2 | Upgrade
|
| EBIT | -55.9 | -47.21 | -41.68 | -167.54 | -204.47 | -186.5 | Upgrade
|
| Revenue as Reported | - | - | 0.72 | 12.8 | 22.41 | 37.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.